156 related articles for article (PubMed ID: 35833529)
1. Delivery of enzalutamide
Gao Z; Huang J; Xie Z; Xin P; Huang H; Du T; Wu J; Huang H
Biomater Sci; 2022 Sep; 10(18):5187-5196. PubMed ID: 35833529
[TBL] [Abstract][Full Text] [Related]
2. Intravenous delivery of enzalutamide based on high drug loading multifunctional graphene oxide nanoparticles for castration-resistant prostate cancer therapy.
Jiang W; Chen J; Gong C; Wang Y; Gao Y; Yuan Y
J Nanobiotechnology; 2020 Mar; 18(1):50. PubMed ID: 32188463
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer.
Xiao L; Tien JC; Vo J; Tan M; Parolia A; Zhang Y; Wang L; Qiao Y; Shukla S; Wang X; Zheng H; Su F; Jing X; Luo E; Delekta A; Juckette KM; Xu A; Cao X; Alva AS; Kim Y; MacLeod AR; Chinnaiyan AM
Cancer Res; 2018 Oct; 78(20):5731-5740. PubMed ID: 30135193
[TBL] [Abstract][Full Text] [Related]
5. IU1 and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer.
Zhang Y; Liao Y; Luo M; Ye Y; Xu Z; Hou W; Liu R; Zhai Q; Lv S; Wei Q
Prostate; 2023 Nov; 83(15):1446-1457. PubMed ID: 37545197
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it.
Wang Y; Chen J; Wu Z; Ding W; Gao S; Gao Y; Xu C
Br J Pharmacol; 2021 Jan; 178(2):239-261. PubMed ID: 33150960
[TBL] [Abstract][Full Text] [Related]
7. Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.
Graham L; Schweizer MT
Med Oncol; 2016 May; 33(5):44. PubMed ID: 27042852
[TBL] [Abstract][Full Text] [Related]
8. Aberrant activation of super enhancer and choline metabolism drive antiandrogen therapy resistance in prostate cancer.
Wen S; He Y; Wang L; Zhang J; Quan C; Niu Y; Huang H
Oncogene; 2020 Oct; 39(42):6556-6571. PubMed ID: 32917955
[TBL] [Abstract][Full Text] [Related]
9. ASC-J9(®) suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L.
Wang R; Lin W; Lin C; Li L; Sun Y; Chang C
Cancer Lett; 2016 Aug; 379(1):154-60. PubMed ID: 27233475
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment Neutrophil to Lymphocyte Ratio (NLR) Predicts Prognosis for Castration Resistant Prostate Cancer Patients Underwent Enzalutamide.
Kumano Y; Hasegawa Y; Kawahara T; Yasui M; Miyoshi Y; Matsubara N; Uemura H
Biomed Res Int; 2019; 2019():9450838. PubMed ID: 30800682
[TBL] [Abstract][Full Text] [Related]
11. Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer.
Chou FJ; Lin C; Tian H; Lin W; You B; Lu J; Sahasrabudhe D; Huang CP; Yang V; Yeh S; Niu Y; Chang C
Cell Death Dis; 2020 Nov; 11(11):942. PubMed ID: 33139720
[TBL] [Abstract][Full Text] [Related]
12. Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7).
Lin SJ; Chou FJ; Li L; Lin CY; Yeh S; Chang C
Cancer Lett; 2017 Jul; 398():62-69. PubMed ID: 28373004
[TBL] [Abstract][Full Text] [Related]
13. Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
Altavilla A; Casadei C; Lolli C; Menna C; Ravaglia G; Gurioli G; Farolfi A; Brighi N; Conteduca V; Burgio SL; Schepisi G; Rossi L; Gargiulo S; Lisotti I; De Giorgi U
Expert Opin Pharmacother; 2020 Dec; 21(17):2091-2099. PubMed ID: 32783772
[TBL] [Abstract][Full Text] [Related]
14. Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer.
Rajaram P; Rivera A; Muthima K; Olveda N; Muchalski H; Chen QH
Molecules; 2020 May; 25(10):. PubMed ID: 32456317
[TBL] [Abstract][Full Text] [Related]
15. Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer.
Kregel S; Chen JL; Tom W; Krishnan V; Kach J; Brechka H; Fessenden TB; Isikbay M; Paner GP; Szmulewitz RZ; Vander Griend DJ
Oncotarget; 2016 May; 7(18):26259-74. PubMed ID: 27036029
[TBL] [Abstract][Full Text] [Related]
16. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.
Liu C; Lou W; Zhu Y; Nadiminty N; Schwartz CT; Evans CP; Gao AC
Clin Cancer Res; 2014 Jun; 20(12):3198-3210. PubMed ID: 24740322
[TBL] [Abstract][Full Text] [Related]
17. CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer.
Chen X; Wu Y; Wang X; Xu C; Wang L; Jian J; Wu D; Wu G
Eur J Med Res; 2022 Jul; 27(1):105. PubMed ID: 35780240
[TBL] [Abstract][Full Text] [Related]
18. Targeting AR-Beclin 1 complex-modulated growth factor signaling increases the antiandrogen Enzalutamide sensitivity to better suppress the castration-resistant prostate cancer growth.
Zhang M; Sun Y; Meng J; Zhang L; Liang C; Chang C
Cancer Lett; 2019 Feb; 442():483-490. PubMed ID: 30423407
[TBL] [Abstract][Full Text] [Related]
19. Structural and molecular insights into the mechanism of resistance to enzalutamide by the clinical mutants in androgen receptor (AR) in castration-resistant prostate cancer (CRPC) patients.
Khan A; Mao Y; Tahreem S; Wei DQ; Wang Y
Int J Biol Macromol; 2022 Oct; 218():856-865. PubMed ID: 35905763
[TBL] [Abstract][Full Text] [Related]
20. Endosomal recycling inhibitors downregulate the androgen receptor and synergise with enzalutamide.
Fletcher KA; Alkurashi MH; Lindsay AJ
Invest New Drugs; 2024 Feb; 42(1):14-23. PubMed ID: 37957513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
